Author: Ouédraogo, Dieu-Donné; Tiendrébéogo, Wendlassida Joelle Stéphanie; Kaboré, Fulgence; Ntsiba, Honoré
Title: COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments Cord-id: jzm1c7ur Document date: 2020_5_29
ID: jzm1c7ur
Snippet: Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF α) in the body by COVID-19 in its severe form. In this review, the authors make t
Document: Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF α) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment.
Search related documents:
Co phrase search for related documents- aak1 inhibitor and lopinavir ritonavir: 1
- ace related enzyme and acute severe: 1, 2, 3, 4, 5, 6, 7
- ace related enzyme and lung damage: 1
- ace related enzyme and lung injury: 1
- action potential mechanism and acute respiratory distress syndrome: 1, 2
- action potential mechanism and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9
- action potential mechanism and lopinavir ritonavir: 1
- action potential mechanism and lung damage: 1
- action potential mechanism and lung disease: 1
- action potential mechanism and lung injury: 1, 2, 3
- action potential mechanism and lupus erythematosus: 1
- acute respiratory death lead distress syndrome and lung damage: 1
- acute respiratory death lead distress syndrome and lung injury: 1, 2, 3
- acute respiratory distress syndrome and loading dose: 1, 2, 3, 4
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung fluid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date